U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Aggressive Adult Non-Hodgkin Lymphoma

MedGen UID:
146179
•Concept ID:
C0677726
•
Neoplastic Process
Synonyms: Aggressive Recurrent Adult Non-Hodgkin's Lymphoma; Recurrent Adult Aggressive Non-Hodgkin's Lymphoma; Recurrent Aggressive Adult Non-Hodgkin's Lymphoma

Definition

The reemergence of an aggressive adult non-Hodgkin lymphoma after a period of remission. [from NCI]

Professional guidelines

PubMed

T cell lymphoma: time to make discoveries and advance treatment.
Ishitsuka K
Int J Hematol 2023 Apr;117(4):473-474. Epub 2023 Mar 14 doi: 10.1007/s12185-023-03573-3. PMID: 36918503
Diagnosis, prevention and treatment of central nervous system involvement in peripheral t-cell lymphomas.
Zing N, Fischer T, Federico M, Chiattone C, Ferreri AJM
Crit Rev Oncol Hematol 2021 Nov;167:103496. Epub 2021 Oct 12 doi: 10.1016/j.critrevonc.2021.103496. PMID: 34653598
Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma.
Moleti ML, Testi AM, Foà R
Br J Haematol 2020 Jun;189(5):826-843. Epub 2020 Mar 6 doi: 10.1111/bjh.16461. PMID: 32141616

Recent clinical studies

Etiology

How I treat secondary CNS involvement by aggressive lymphomas.
Alderuccio JP, Nayak L, Cwynarski K
Blood 2023 Nov 23;142(21):1771-1783. doi: 10.1182/blood.2023020168. PMID: 37702537Free PMC Article
CAR T-cell therapy for B-cell lymphoma.
Denlinger N, Bond D, Jaglowski S
Curr Probl Cancer 2022 Feb;46(1):100826. Epub 2021 Dec 25 doi: 10.1016/j.currproblcancer.2021.100826. PMID: 35012754Free PMC Article
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu JM, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Martinez-Prieto M, Han X, Tiwari R, Salles G, Maziarz RT
Lancet Oncol 2021 Oct;22(10):1403-1415. Epub 2021 Sep 10 doi: 10.1016/S1470-2045(21)00375-2. PMID: 34516954
Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma.
Moleti ML, Testi AM, Foà R
Br J Haematol 2020 Jun;189(5):826-843. Epub 2020 Mar 6 doi: 10.1111/bjh.16461. PMID: 32141616
How I treat patients with aggressive lymphoma at high risk of CNS relapse.
Chin CK, Cheah CY
Blood 2017 Aug 17;130(7):867-874. Epub 2017 Jun 13 doi: 10.1182/blood-2017-03-737460. PMID: 28611025

Diagnosis

Burkitt lymphoma.
López C, Burkhardt B, Chan JKC, Leoncini L, Mbulaiteye SM, Ogwang MD, Orem J, Rochford R, Roschewski M, Siebert R
Nat Rev Dis Primers 2022 Dec 15;8(1):78. doi: 10.1038/s41572-022-00404-3. PMID: 36522349
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu JM, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Martinez-Prieto M, Han X, Tiwari R, Salles G, Maziarz RT
Lancet Oncol 2021 Oct;22(10):1403-1415. Epub 2021 Sep 10 doi: 10.1016/S1470-2045(21)00375-2. PMID: 34516954
Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma.
Moleti ML, Testi AM, Foà R
Br J Haematol 2020 Jun;189(5):826-843. Epub 2020 Mar 6 doi: 10.1111/bjh.16461. PMID: 32141616
Cartilage-hair hypoplasia with normal height in childhood-4 patients with a unique genotype.
Klemetti P, Valta H, Kostjukovits S, Taskinen M, Toiviainen-Salo S, Mäkitie O
Clin Genet 2017 Aug;92(2):204-207. Epub 2017 Mar 19 doi: 10.1111/cge.12969. PMID: 28094436
Changing the paradigms of treatment in peripheral T-cell lymphoma: from biology to clinical practice.
O'Connor OA, Bhagat G, Ganapathi K, Pedersen MB, D'Amore F, Radeski D, Bates SE
Clin Cancer Res 2014 Oct 15;20(20):5240-54. doi: 10.1158/1078-0432.CCR-14-2020. PMID: 25320373

Therapy

Relapse after glofitamab has a poor prognosis and rates of CD20 loss are high.
Grigg S, Minson A, Prins E, Dickinson MJ
Br J Haematol 2024 Jul;205(1):122-126. Epub 2024 May 8 doi: 10.1111/bjh.19455. PMID: 38720530
SOHO State of the Art Updates and Next Questions | Immunotherapeutic Options for Patients With Mantle Cell Lymphoma Who Progress on BTK Inhibitors.
Nayak RK, Gerber D, Zhang C, Cohen JB
Clin Lymphoma Myeloma Leuk 2023 Dec;23(12):861-865. Epub 2023 Aug 14 doi: 10.1016/j.clml.2023.08.011. PMID: 37661513
CAR T-cell therapy for B-cell lymphoma.
Denlinger N, Bond D, Jaglowski S
Curr Probl Cancer 2022 Feb;46(1):100826. Epub 2021 Dec 25 doi: 10.1016/j.currproblcancer.2021.100826. PMID: 35012754Free PMC Article
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu JM, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Martinez-Prieto M, Han X, Tiwari R, Salles G, Maziarz RT
Lancet Oncol 2021 Oct;22(10):1403-1415. Epub 2021 Sep 10 doi: 10.1016/S1470-2045(21)00375-2. PMID: 34516954
Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma.
Moleti ML, Testi AM, Foà R
Br J Haematol 2020 Jun;189(5):826-843. Epub 2020 Mar 6 doi: 10.1111/bjh.16461. PMID: 32141616

Prognosis

Relapse after glofitamab has a poor prognosis and rates of CD20 loss are high.
Grigg S, Minson A, Prins E, Dickinson MJ
Br J Haematol 2024 Jul;205(1):122-126. Epub 2024 May 8 doi: 10.1111/bjh.19455. PMID: 38720530
Allogeneic Hematopoietic Stem Cell Transplant for Diffuse Large B-Cell Lymphoma: Evolving Role in the Era of CAR T-Cell Therapy.
Hilal T, Mountjoy LJ
Curr Oncol Rep 2023 Jun;25(6):599-607. Epub 2023 Mar 28 doi: 10.1007/s11912-023-01403-7. PMID: 36976461
An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma.
Izutsu K, Makita S, Nosaka K, Yoshimitsu M, Utsunomiya A, Kusumoto S, Morishima S, Tsukasaki K, Kawamata T, Ono T, Rai S, Katsuya H, Ishikawa J, Yamada H, Kato K, Tachibana M, Kakurai Y, Adachi N, Tobinai K, Yonekura K, Ishitsuka K
Blood 2023 Mar 9;141(10):1159-1168. doi: 10.1182/blood.2022016862. PMID: 36150143Free PMC Article
Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma.
Moleti ML, Testi AM, Foà R
Br J Haematol 2020 Jun;189(5):826-843. Epub 2020 Mar 6 doi: 10.1111/bjh.16461. PMID: 32141616
Tumor Microenvironment in T-Cell Lymphomas.
Bennani NN, Ansell SM
Cancer Treat Res 2019;176:69-82. doi: 10.1007/978-3-319-99716-2_3. PMID: 30596213

Clinical prediction guides

Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study.
Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, Matasar MJ, Bosch F, Kim WS, Nastoupil LJ, Flinn IW, Shadman M, Diefenbach C, Cheah CY, Ma CY, Huang H, Kwan A, Wei MC, Yin S, Bartlett NL
J Clin Oncol 2024 Jul 1;42(19):2250-2256. Epub 2024 Mar 28 doi: 10.1200/JCO.23.02329. PMID: 38547425Free PMC Article
How I treat secondary CNS involvement by aggressive lymphomas.
Alderuccio JP, Nayak L, Cwynarski K
Blood 2023 Nov 23;142(21):1771-1783. doi: 10.1182/blood.2023020168. PMID: 37702537Free PMC Article
Comparison of chidamide-contained treatment modalities versus chemotherapy in the second-line treatment for relapsed or refractory peripheral T-cell lymphoma.
Wang J, Fang Y, Ma S, Su N, Zhang Y, Huang H, Li Z, Huang H, Tian X, Cai J, Xia Y, Liu P, Cai Q
Leuk Res 2021 Dec;111:106705. Epub 2021 Sep 14 doi: 10.1016/j.leukres.2021.106705. PMID: 34534908
A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma.
Dreyling M, Tam CS, Wang M, Smith SD, Ladetto M, Huang H, Novotny W, Co M, Romano A, Holmgren E, Huang J, Gouill SL
Future Oncol 2021 Jan;17(3):255-262. Epub 2020 Sep 28 doi: 10.2217/fon-2020-0794. PMID: 32985902
CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, Glass B, Scott DW, Gascoyne RD, Connors JM, Ziepert M, Pfreundschuh M, Loeffler M, Savage KJ
J Clin Oncol 2016 Sep 10;34(26):3150-6. Epub 2016 Jul 5 doi: 10.1200/JCO.2015.65.6520. PMID: 27382100

Recent systematic reviews

A systematic overview of radiation therapy effects in non-Hodgkin's lymphoma.
Gustavsson A, Osterman B, Cavallin-Ståhl E
Acta Oncol 2003;42(5-6):605-19. doi: 10.1080/02841860310014435. PMID: 14596518
A systematic overview of chemotherapy effects in aggressive non-Hodgkin's lymphoma.
Kimby E, Brandt L, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care
Acta Oncol 2001;40(2-3):198-212. doi: 10.1080/02841860151116268. PMID: 11441932

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...